Venrock Adviser, LLC
NEW YORK, NY · CIK 1615982 · 13F filing filed 2021-05-14
SEC-registered investment adviser since 2014 · limited liability company
- Assets managed$4.5bn
- Staff11 · 11 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds7 (1 hedge) · $4.5bn gross assets
- Form ADV · 2026-04-28SEC adviser record
- Legal entityVENROCK ADVISER, LLC (US)
- Kindhedge funds, private equity
- Others nearbyNew York, NY, Palo Alto, CA
As an employer
- Offices in1 country
- Private fundshedge 1, private equity 6
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| New York, NY (main office)United States | about 11 |
| Palo Alto, CAUnited States |
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
$921.8m
reported value
+35.5% vs Q4 2020
28positions
73.1%in top 10
7 new
7 added
5 reduced
4 sold out
vs Q4 2020
Holdings, Q1 2021
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| INSTIL BIO INC COM | $172.2m18.68% | New |
| CONSTELLATION PHARMCETICLS I CNST | $94.0m10.19% | Unchanged |
| ACLARIS THERAPEUTICS INC ACRS | $93.8m10.17% | Added +1.8m |
| OLEMA PHARMACEUTICALS INC OLMA | $51.0m5.53% | Unchanged |
| ALTIMMUNE INC ALT | $49.5m5.37% | Reduced -1.0m |
| CULLINAN THERAPEUTICS INC CGEM | $49.0m5.32% | New |
| KINNATE BIOPHARMA INC KNTE | $45.9m4.98% | Unchanged |
| TRILLIUM THERAPEUTICS INC TR | $43.4m4.71% | Unchanged |
| MARINUS PHARMACEUTICALS INC MRNS | $40.9m4.44% | Added +52.9k |
| VISTAGEN THERAPEUTICS INC VTGN | $34.7m3.77% | Added +6.9m |
| ATHIRA PHARMA INC COM | $31.1m3.38% | Unchanged |
| RELMADA THERAPEUTICS INC RLMD | $30.0m3.26% | Added +184.8k |
| CELLDEX THERAPEUTICS INC NEW CLDX | $25.6m2.77% | Added +440.6k |
| PHARVARIS N V PHVS | $25.3m2.75% | New |
| KEROS THERAPEUTICS INC KROS | $22.9m2.49% | Reduced -300.0k |
| ESSA PHARMA INC EPI | $18.2m1.97% | New |
| KURA ONCOLOGY INC KURA | $16.3m1.76% | Unchanged |
| SYNDAX PHARMACEUTICALS INC SNDX | $13.2m1.44% | Reduced -523.5k |
| ADICET BIO INC COM | $13.1m1.42% | New |
| APTOSE BIOSCIENCES INC COM NEW | $9.6m1.04% | New |
| COGENT BIOSCIENCES INC COGT | $9.6m1.04% | Unchanged |
| ALIGOS THERAPEUTICS INC COM | $9.3m1.01% | Added +3.5k |
| EYEPOINT PHARMACEUTICALS INC EYPT | $7.1m0.77% | New |
| BCTG ACQUISITION CORP COM | $5.6m0.60% | Unchanged |
| METACRINE INC COM | $4.2m0.46% | Reduced -13.7k |
| ARS PHARMACEUTICALS INC SPRY | $3.7m0.40% | Reduced -65.0k |
| TAYSHA GENE THERAPIES INC TSHA | $2.4m0.27% | Added +12.7k |
| VIRIDIAN THERAPEUTICS INC VRDN | $326.0k0.04% | Unchanged |
Sold out since Q4 2020
| Security | Value then |
|---|---|
| SURFACE ONCOLOGY INC SURF | $13.3m1.4m shares |
| GALERA THERAPEUTICS INC | $9.4m917.9k shares |
| FIVE PRIME THERAPEUTICS INC FPRX | $4.2m245.1k shares |
| BIOATLA INC BCAB | $3.4m100.0k shares |